Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea

키워드

참고문헌 (66)

1. "NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Version 2" (2011)[URL]
2. Casali PG, "ESMO", CONTICANET, Ann Oncol, pp.2010, 21(Suppl 5)[DOI]
3. Nishida T, "Clinical practice guidelines for gastrointestinal stromal tumor(GIST)in Japan : English version", Int J Clin Oncol, 13, pp.416~430 (2008)
4. "National Comprehensive Cancer Network Practice Guidelines in Oncology Soft Tissue Sarcoma. J Natl Compr Canc Netw internet" (2011)[URL]
5. Korean Gastrointestinal Stromal Tumor Study Group, "Clinical practice guideline for adequate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea", J Korean Med Assoc, 50, pp.830~841 (2007)
6. 강윤구, "Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea", Journal of Korean Medical Science, 25(11), pp.1543~1552 (2010), 대한의학회
7. Nelson H, "Guidelines 2000 for colon and rectal cancer surgery", J Natl Cancer Inst, 93, pp.583~596 (2001)
8. Kang DY, "Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients", AMER J SURG PATHOL, 31, pp.224~232 (2007), Lippincott Williams & Wilkins
9. Rubin BP, "Gastrointestinal stromal tumour", Lancet, 369, pp.1731~1741 (2007)
10. Kyoung-Mee Kim, "Gastrointestinal Stromal Tumors in Koreans:It's Incidence and the Clinical,Pathologic and Immunohistochemical Findings", Journal of Korean Medical Science, 20(6), pp.977~984 (2005), 대한의학회
11. 조미연, "Current Trends in the Epidemiological and Pathological Characteristics of Gastrointestinal Stromal Tumors in Korea, 2003-2004", Journal of Korean Medical Science, 25(6), pp.853~862 (2010), 대한의학회
12. Demetri GD, "NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)―update of the NCCN clinical practice guidelines", J Natl Compr Canc Netw, 5(Suppl 2), pp.S1~S29 (2007)
13. Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
14. Miettinen M, "Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age", Am J Surg Pathol, 35, pp.1712~1721 (2011)
15. Miettinen M, "Gastrointestinal stromal tumors : review on morphology, molecular pathology, prognosis, and differential diagnosis", Arch Pathol Lab Med, 130, pp.1466~1478 (2006)
16. Fletcher CD, "Diagnosis of gastrointestinal stromal tumors : a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
17. Liegl B, "Contemporary pathology of gastrointestinal stromal tumors", Hematol Oncol Clin North Am, 23, pp.49~68 (2009)
18. Kang GH, "DOG-1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors", Mod Pathol, 24, pp.866~875 (2011)
19. Kim KM, "PKCtheta expression in gastrointestinal stromal tumor", Mod Pathol, 19, pp.1480~1486 (2006)
20. Lee HE, "Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining", JOURNAL OF CLINICAL PATHOLOGY, 61, pp.722~729 (2008), B M J PUBLISHING GROUP
21. Orosz Z, "Gastrointestinal stromal tumors : a clinicopathologic and immunohistochemical study of 136 cases", Pathol Oncol Res, 11, pp.11~21 (2005)
22. Medeiros F, "KIT-negative gastrointestinal stromal tumors : proof of concept and therapeutic implications", Am J Surg Pathol, 28, pp.889~894 (2004)
23. Miettinen M, "DOG-1 antibody in the differential diagnosis of gastrointestinal stromal tumors : a study of 1840 cases", Am J Surg Pathol, 33, pp.1401~1408 (2009)
24. Miettinen M, "Gastrointestinal stromal tumors : pathology and prognosis at different sites", Semin Diagn Pathol, 23, pp.70~83 (2006)
25. Miettinen M, "Gastrointestinal stromal tumors : recent advances in understanding of their biology", Hum Pathol, 30, pp.1213~1220 (1999)
26. Blay JY, "Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO", Ann Oncol, 16, pp.566~578 (2005)
27. Brunicardi FC, "Schwartz′s principles of surgery. 8th ed" (2005), McGraw-Hill
28. Townsend CM Jr, "Sabiston textbook of surgery: the biological basis of modern surgical practice. 17th ed" (2004), W.B. Saunders Co.
29. Trent JC, "New developments in gastrointestinal stromal tumor", Curr Opin Oncol, 18, pp.386~395 (2006)
30. Ryu MH, "Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate", Jpn J Clin Oncol, 36, pp.17~24 (2006)
31. Gold JS, "Combined surgical and molecular therapy : the gastrointestinal stromal tumor model", Ann Surg, 244, pp.176~184 (2006)
32. Iwahashi M, "Surgical management of small gastrointestinal stromal tumors of the stomach", World J Surg, 30, pp.28~35 (2006)
33. Choi SM, "Laparoscopic wedge resection for gastric GIST : long-term follow-up results", Eur J Surg Oncol, 33, pp.444~447 (2007)
34. Novitsky YW, "Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors", Ann Surg, 243, pp.738~745 (2006)
35. Otani Y, "Operative indications for relatively small(2-5 cm)gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases", Surgery, 139, pp.484~492 (2006)
36. Pister PW, "GIST guidelines: from evidence to practice, evolving consensus in GIST management meeting monograph. In: GIST Global Opinion Leader Summit" (2007)
37. DeMatteo RP, "Two hundred gastrointestinal stromal tumors : recurrence patterns and prognostic factors for survival", Ann Surg, 231, pp.51~58 (2000)
38. Raut CP, "Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors", J Clin Oncol, 24, pp.2325~2331 (2006)
39. 심선진, "Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)", JOURNAL OF SURGICAL ONCOLOGY, 98(1), pp.27~33, WILEY-LISS
40. DeMatteo RP, "Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour : a randomised, double-blind, placebo-controlled trial", Lancet, 373, pp.1097~1104 (2009)
41. Kang B, "A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors", J Clin Oncol, 27(S), pp.e21515~ (2009)
42. Kim TW, "Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors", ONCOLOGIST, 14(5), pp.540~547 (2009), ALPHAMED PRESS
43. Joensuu H, "Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII", AIO), 2011, pp.29(S), LBA1~
44. Joensuu H, "Risk stratification of patients diagnosed with gastrointestinal stromal tumor", Hum Pathol, 39, pp.1411~1419 (2008)
45. Bumming P, "Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours(GIST)with imatinib : a centre-based study of 17 patients", Br J Cancer, 89, pp.460~464 (2003)
46. Loughrey MB, "Gastrointestinal stromal tumour treated with neoadjuvant imatinib", J Clin Pathol, 58, pp.779~781 (2005)
47. Ji Seon Oh, "Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases", Cancer Research and Treatment, 38(3), pp.179~183 (2006), 대한암학회
48. DeMatteo RP, "Clinical management of gastrointestinal stromal tumors : before and after STI-571", Hum Pathol, 33, pp.466~477 (2002)
49. Rankin C, "Dose effect of imatinib (im) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033", J Clin Oncol, 22(14S), pp.9005~ (2004)
50. Verweij J, "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial", Lancet, 364, pp.1127~1134 (2004)
51. Debiec-Rychter M, "KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours", Eur J Cancer, 42, pp.1093~1103 (2006)
52. Du CY, "The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor(GIST)", J Surg Oncol, 98, pp.175~178 (2008)
53. Yeh CN, "Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST : preliminary experience from Chang Gung Memorial Hospital", Ann Surg Oncol, 14, pp.1123~1128 (2007)
54. Kang HJ, "Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors(GIST) : The Korean GIST Study Group(KGSG)study", Acta Oncol, 51, pp.528~536 (2012)
55. Domont J, "Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized phase III trial", J Clin Oncol, 29(S), pp.10054~ (2011)
56. Antoch G, "Comparison of PET, CT, and dual-modality PET", CT imaging for monitoring of imatinib(STI571)therapy in patients with gastrointestinal stromal tumors, 2004, pp.45, 357~365
57. Jager PL, "Imatinib mesylate for the treatment of gastrointestinal stromal tumours : best monitored with FDG PET", Nucl Med Commun, 25, pp.433~438 (2004)
58. Stroobants S, "18FDGPositron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate(Glivec)", Eur J Cancer, 39, pp.2012~2020 (2003)
59. Choi H, "CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment : a quantitative analysis correlated with FDG PET findings", AJR Am J Roentgenol, 183, pp.1619~1628 (2004)
60. Choi H, "Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate : proposal of new computed tomography response criteria", J Clin Oncol, 25, pp.1753~1759 (2007)
61. Linton KM, "Response evaluation in gastrointestinal stromal tumours treated with imatinib: Misdiagnosis of disease progression on CT due to cystic change in liver metastases", Br J Cancer, 79, pp.e40~e44 (2006)
62. Desai J, "Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions", J Clin Oncol, 22(14S), pp.3010~ (2004)
63. Bauer S, "Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib", Int J Cancer, 117, pp.316~325 (2005)
64. Zalcberg JR, "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg", Eur J Cancer, 41, pp.1751~1757 (2005)
65. Park I, "Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor", Jpn J Clin Oncol, 39, pp.105~110 (2009)
66. Demetri GD, "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial", Lancet, 368, pp.1329~1338 (2006)

관련 논문AI추천